Table 2.
Variable | Number of patients | Disease-free survival (%) | Univariate | Multivariate | |||||
---|---|---|---|---|---|---|---|---|---|
Total | With recurrence | 1-year | 3-year | HR (95% CI) | p value | ||||
Age (years) | ≤64 | 27 | 5 | 96.3 | 86.5 | 1 (ref. group) | 0.15 | ||
>64 | 27 | 9 | 77.8 | 70.7 | 2.24 (0.75–6.74) | ||||
| |||||||||
Sex | Female | 28 | 8 | 92.9 | 76.0 | 1.42 (0.48–4.16) | 0.53 | ||
Male | 26 | 6 | 80.8 | 80.8 | 1 (ref. group) | ||||
| |||||||||
Tumour size (cm) | ≤5 | 31 | 5 | 96.8 | 93.1 | 1 (ref. group) | 0.039 | ||
>5 | 23 | 9 | 73.9 | 57.5 | 3.19 (1.06–9.61) | ||||
| |||||||||
Tumour location | Gastric | 40 | 8 | 87.5 | 78.3 | 1 (ref. group) | 0.31 | ||
Non-gastric | 14 | 6 | 85.7 | 77.1 | 1.73 (0.60–5.04) | ||||
| |||||||||
ESMO group | 1 or 2 | 27 | 4 | 100.0 | 95.8 | 1 (ref. group) | 0.043 | ||
3 or more | 27 | 10 | 74.1 | 60.6 | 3.34 (1.04–10.76) | ||||
| |||||||||
CD63 | 0-1 | 38 | 7 | 100.0 | 89.6 | 1 (ref. group) | 0.008 | ||
2-3 | 16 | 7 | 56.3 | 56.3 | 4.52 (1.49–13.73) | 3.48 (1.10–10.96) | 0.033 | ||
| |||||||||
GLUT-1 | 0-1 | 29 | 3 | 96.6 | 96.7 | 1 (ref. group) | 0.014 | 1 (ref. group) | |
2-3 | 25 | 11 | 76.0 | 58.0 | 5.00 (1.39–17.96) | 4.05 (1.10–14.89) | 0.036 | ||
| |||||||||
CD9 | 0–2 | 8 | 0 | 100.0 | — | — | — | ||
3 | 46 | 14 | 84.8 | 74.9 | — |